Fox Run Management L.L.C. Makes New Investment in Enfusion, Inc. (NYSE:ENFN)

Fox Run Management L.L.C. purchased a new stake in Enfusion, Inc. (NYSE:ENFN) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 25,736 shares of the company’s stock, valued at approximately $265,000.

Several other institutional investors have also made changes to their positions in ENFN. Centiva Capital LP increased its stake in Enfusion by 5.0% during the 3rd quarter. Centiva Capital LP now owns 25,596 shares of the company’s stock worth $243,000 after acquiring an additional 1,227 shares during the period. Rhumbline Advisers increased its position in shares of Enfusion by 3.0% in the fourth quarter. Rhumbline Advisers now owns 62,464 shares of the company’s stock worth $643,000 after purchasing an additional 1,796 shares during the period. Azora Capital LP raised its stake in Enfusion by 6.8% in the third quarter. Azora Capital LP now owns 29,827 shares of the company’s stock valued at $283,000 after purchasing an additional 1,890 shares in the last quarter. Bank of New York Mellon Corp lifted its position in Enfusion by 3.3% during the fourth quarter. Bank of New York Mellon Corp now owns 126,541 shares of the company’s stock worth $1,303,000 after purchasing an additional 4,032 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its stake in Enfusion by 1.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 371,151 shares of the company’s stock worth $3,823,000 after buying an additional 5,639 shares in the last quarter. 81.05% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on ENFN. William Blair restated a “market perform” rating on shares of Enfusion in a research report on Monday, January 13th. Piper Sandler upped their target price on Enfusion from $10.00 to $11.50 and gave the stock a “neutral” rating in a research note on Monday, December 23rd. Finally, Stifel Nicolaus raised their price objective on Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a research note on Wednesday, December 18th.

Insider Transactions at Enfusion

In other Enfusion news, COO Neal Pawar sold 2,769 shares of Enfusion stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $11.48, for a total transaction of $31,788.12. Following the transaction, the chief operating officer now directly owns 1,231,627 shares of the company’s stock, valued at approximately $14,139,077.96. The trade was a 0.22 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Oleg Movchan sold 2,771 shares of the firm’s stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $10.13, for a total value of $28,070.23. Following the transaction, the chief executive officer now owns 526,702 shares of the company’s stock, valued at $5,335,491.26. This trade represents a 0.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 77,346 shares of company stock worth $868,109. Insiders own 36.44% of the company’s stock.

Enfusion Price Performance

Shares of Enfusion stock opened at $11.15 on Friday. The company’s 50 day moving average price is $11.18 and its two-hundred day moving average price is $10.16. The firm has a market capitalization of $1.44 billion, a P/E ratio of 278.69, a P/E/G ratio of 1.85 and a beta of 0.95. Enfusion, Inc. has a fifty-two week low of $7.83 and a fifty-two week high of $11.80.

Enfusion (NYSE:ENFN) last released its quarterly earnings data on Monday, March 3rd. The company reported $0.01 earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.02). Enfusion had a net margin of 1.70% and a return on equity of 6.67%. The firm had revenue of $52.94 million for the quarter, compared to analyst estimates of $53.98 million. On average, analysts expect that Enfusion, Inc. will post 0.06 earnings per share for the current year.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.